MGTX
MeiraGTx Holdings plc NASDAQ Listed Jun 8, 2018$11.32
+8.74%
vs $10.41
Mkt Cap $1.0B
52w Low $6.07
90.8% of range
52w High $11.85
50d MA $9.70
200d MA $8.41
P/E (TTM)
-8.0x
EV/EBITDA
—
P/B
—
Debt/Equity
-15.3x
ROE
1971.4%
P/FCF
-18.1x
RSI (14)
56.90
ATR (14)
$0.60
Beta
1.28
50d MA
$9.70
200d MA
$8.41
Avg Volume
809.3K
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
430 East 29th Street · New York City, NY 10016 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | BMO | -0.58 | -0.57 | +1.7% | 9.97 | +0.1% | -0.2% | -5.5% | +0.0% | -2.9% | +4.9% | — |
| May 13, 2026 | BMO | — | — | — | 9.79 | -0.3% | +1.8% | -0.2% | -5.5% | +0.0% | -2.9% | — |
| May 12, 2026 | BMO | — | — | — | 9.90 | -2.0% | -1.1% | +1.8% | -0.2% | -5.5% | +0.0% | — |
| Mar 26, 2026 | BMO | -0.60 | 0.19 | +131.7% | 7.53 | +2.0% | +1.2% | +6.2% | +7.0% | +5.0% | +1.0% | — |
| Nov 13, 2025 | BMO | -0.50 | -0.62 | -24.0% | 8.26 | -1.8% | -0.8% | -3.8% | -1.6% | -2.2% | -2.0% | — |
| Aug 14, 2025 | BMO | -0.52 | -0.48 | +7.7% | 8.33 | -1.2% | -1.9% | -2.4% | -4.9% | -0.3% | +3.8% | — |
| May 13, 2025 | BMO | -0.38 | -0.51 | -34.2% | 5.15 | -1.0% | -9.9% | +8.6% | -1.0% | +3.2% | +6.8% | — |
| Mar 13, 2025 | BMO | -0.48 | -0.50 | -4.2% | 8.25 | +3.8% | -5.6% | +1.0% | -4.7% | +3.6% | -1.5% | — |
| Nov 13, 2024 | BMO | -0.47 | -0.54 | -14.9% | 7.04 | +1.7% | -5.7% | -2.4% | -6.0% | -1.8% | -2.7% | — |
| Aug 12, 2024 | BMO | -0.31 | -0.76 | -145.2% | 4.00 | -0.8% | +5.5% | -5.2% | +10.0% | -3.9% | +1.9% | — |
| May 9, 2024 | BMO | -0.32 | -0.77 | -140.6% | 5.10 | +1.4% | -0.6% | +1.4% | +1.8% | +5.7% | +2.7% | — |
| Mar 14, 2024 | BMO | -0.46 | -0.47 | -2.2% | 5.90 | -1.5% | +7.6% | -2.4% | +1.3% | +3.3% | -0.5% | — |
| Nov 14, 2023 | BMO | -0.63 | -0.74 | -17.5% | 4.84 | -1.4% | +2.3% | +3.2% | +10.4% | +0.4% | -3.2% | — |
| Aug 10, 2023 | BMO | -0.59 | -0.53 | +10.2% | 6.00 | +1.2% | +1.2% | -1.8% | -2.0% | -0.2% | -0.5% | — |
| May 11, 2023 | BMO | -0.65 | -0.62 | +4.6% | 5.83 | +1.9% | -1.0% | +6.6% | +13.8% | +10.0% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.17 | $10.58 | +4.0% | -1.4% | -7.1% | -1.0% | -1.1% | -0.5% |
| Apr 17 | RBC Capital | Maintains | Outperform → Outperform | — | $9.48 | $9.65 | +1.8% | +6.8% | +4.1% | -3.4% | -1.4% | -7.1% |
| Apr 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $8.66 | $8.77 | +1.3% | +5.0% | +1.0% | +3.7% | -0.1% | -1.3% |
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $7.53 | $7.68 | +2.0% | +1.2% | +6.2% | +7.0% | +5.0% | +1.0% |
| Mar 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.53 | $7.68 | +2.0% | +1.2% | +6.2% | +7.0% | +5.0% | +1.0% |
| Mar 27 | BofA Securities | Maintains | Buy → Buy | — | $7.53 | $7.68 | +2.0% | +1.2% | +6.2% | +7.0% | +5.0% | +1.0% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $8.26 | $8.11 | -1.8% | -0.8% | -3.8% | -1.6% | -2.2% | -2.0% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $8.26 | $8.11 | -1.8% | -0.8% | -3.8% | -1.6% | -2.2% | -2.0% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.55 | $8.70 | +1.8% | +4.1% | -2.7% | -4.6% | -0.8% | -3.8% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $8.55 | $8.70 | +1.8% | +4.1% | -2.7% | -4.6% | -0.8% | -3.8% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $8.33 | $8.23 | -1.2% | -1.9% | -2.4% | -4.9% | -0.3% | +3.8% |
| May 14 | Chardan Capital | Maintains | Buy → Buy | — | $5.15 | $5.10 | -1.0% | -9.9% | +8.6% | -1.0% | +3.2% | +6.8% |
| Mar 17 | RBC Capital | Maintains | Outperform → Outperform | — | $7.79 | $7.93 | +1.8% | +1.0% | -4.7% | +3.6% | -1.5% | -1.2% |
| Feb 24 | Chardan Capital | Maintains | Buy → Buy | — | $7.30 | $7.42 | +1.6% | -1.8% | -0.6% | +2.5% | -4.5% | +2.1% |
| Nov 18 | Chardan Capital | Maintains | Buy → Buy | — | $6.48 | $6.49 | +0.2% | -6.0% | -1.8% | -2.7% | +1.7% | +0.2% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $7.04 | $7.16 | +1.7% | -5.7% | -2.4% | -6.0% | -1.8% | -2.7% |
| Aug 13 | RBC Capital | Maintains | Outperform → Outperform | — | $4.00 | $3.97 | -0.8% | +5.5% | -5.2% | +10.0% | -3.9% | +1.9% |
| Jul 31 | Chardan Capital | Maintains | Buy → Buy | — | $4.92 | $5.02 | +2.0% | +6.3% | -6.7% | -2.0% | -6.9% | -0.2% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $5.90 | $5.81 | -1.5% | +7.6% | -2.4% | +1.3% | +3.3% | -0.5% |
| Aug 11 | RBC Capital | Maintains | Outperform → Outperform | — | $6.00 | $6.07 | +1.2% | +1.2% | -1.8% | -2.0% | -0.2% | -0.5% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $6.00 | $6.07 | +1.2% | +1.2% | -1.8% | -2.0% | -0.2% | -0.5% |
| May 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.83 | $5.94 | +1.9% | -1.0% | +6.6% | +13.8% | +10.0% | -0.6% |
| Mar 16 | Chardan Capital | Maintains | Buy → Buy | — | $5.93 | $5.87 | -1.0% | -0.5% | -8.3% | +1.3% | +0.4% | -5.8% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $6.25 | $6.04 | -3.4% | -5.1% | -0.5% | -8.3% | +1.3% | +0.4% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $10.49 | $10.54 | +0.5% | +7.2% | -1.2% | -5.3% | -6.9% | +1.1% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $9.02 | $9.05 | +0.3% | -3.4% | -2.6% | -0.2% | -4.4% | +0.0% |
| May 13 | Barclays | Maintains | Overweight → Overweight | — | $9.02 | $9.05 | +0.3% | -3.4% | -2.6% | -0.2% | -4.4% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 | Forbes Alexandria | PRESIDENT & CEO | Sell | 62,000 | $9.17 | $569K | 1,387,695 | +4.93% | +3.02% |
8-K · 2.02
!! High
MeiraGTx Holdings plc -- 8-K 2.02: Earnings Results
May 14
8-K · 1.01
!! High
MeiraGTx Holdings plc -- 8-K 1.01: Collaboration Agreement
MeiraGTx entered a $105 million collaboration agreement, likely expanding its gene therapy pipeline and providing significant funding for development programs.
Apr 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
MGTX's market research shows strong physician adoption potential for its product, with $3.2-3.7 billion peak revenue projections; this validates the commercial opportunity and could drive significant upside if clinical trials succeed and FDA approval follows.
Apr 16
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
MGTX completed a significant asset acquisition, which could accelerate growth, expand capabilities, or improve profitability—investors should monitor integration costs and synergy realization.
Apr 16
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
MGTX secured underwriting services from BofA Securities for a likely upcoming capital raise, signaling management confidence in funding needs and potentially diluting current shareholders through new share issuance.
Apr 16
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
MGTX secured a strategic partnership with Hologen Limited that could expand its pipeline or commercial reach, making this worth monitoring for potential revenue catalysts or technology synergies.
Mar 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 6,641,064 | $58M | — | Mar 2026 |
| 2 | Millennium Management | 3,465,699 | $30M | Added | Mar 2026 |
| 3 | Morgan Stanley | 3,658,504 | $29M | Added | Dec 2025 |
| 4 | 22nw, Lp | 586,519 | $5M | — | Dec 2025 |
| 5 | D.e. Shaw & Co | 425,281 | $4M | Added | Mar 2026 |
| 6 | Vanguard Portfolio Management Llc | 397,281 | $3M | New | Mar 2026 |
| 7 | Opaleye Management Inc. | 390,844 | $3M | New | Dec 2025 |
| 8 | Ubs Group Ag | 303,198 | $3M | Added | Mar 2026 |
| 9 | Woodline Partners Lp | 300,323 | $3M | — | Mar 2026 |
| 10 | Northern Trust Corp | 271,879 | $2M | Added | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 244,944 | $2M | Added | Mar 2026 |
| 12 | Privium Fund Management B.v. | 212,112 | $2M | Added | Mar 2026 |
| 13 | Nuveen, Llc | 132,454 | $1M | Added | Mar 2026 |
| 14 | Blair William & Co/il | 125,422 | $1M | — | Mar 2026 |
| 15 | Citadel Advisors Llc | 115,995 | $1M | Reduced | Mar 2026 |
| 16 | Bnp Paribas Financial Markets | 111,719 | $967K | Reduced | Mar 2026 |
| 17 | Aqr Capital Management Llc | 110,993 | $961K | Added | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 100,097 | $867K | Reduced | Mar 2026 |
| 19 | Sei Investments Co | 99,627 | $863K | New | Mar 2026 |
| 20 | Russell Investments Group, Ltd. | 97,168 | $841K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.05B
Enterprise Value
$894.2M
P/E (TTM)
-7.97x
Forward P/E
—
PEG Ratio
0.17x
P/B
—
P/S
11.19x
P/FCF
-18.14x
EV/EBITDA
—
Shares Out
80.4M
Financials (TTM)
Revenue
$81.4M
Net Income
-$114.2M
EBITDA
-$106.0M
Free Cash Flow
-$50.2M
Op Cash Flow
-$46.4M
EPS Basic
$-1.42
EPS Diluted
$-1.42
EPS Forward
$-2.42
Gross Margin
94.0%
Op Margin
-130.2%
Net Margin
-140.3%
Balance Sheet
Total Assets
$244.4M
Total Liab.
$250.2M
Total Equity
-$5.8M
Cash
$65.9M
LT Debt
$49.7M
Book Value/Sh
$-0.07
Debt/Equity
-15.31x
Current Ratio
0.75
Quick Ratio
0.75
Returns & Growth
ROE
1971.4%
ROA
-46.7%
ROIC
-70.9%
Rev Growth YoY
+144.6%
EPS Growth YoY
+33.0%
Price Returns
2W
+7.0%
1M
+15.5%
3M
+40.9%
6M
+28.3%
12M
+108.0%
Technicals
52W High
$11.85
52W Low
$6.07
50d MA
$9.70
200d MA
$8.41
RSI (14)
56.90
ATR (14)
$0.60
Beta
1.28
Avg Volume
809K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$23.33
High
$26.00
Low
$20.00
Median
$24.00
Data updated apr 26, 2026 12:10pm
· Source: financialmodelingprep.com